Passion for Health
삼성바이오에피스는 더 많은 환자들에게 고품질의 바이오의약품을 합리적인 가격으로 사용할 수 있는 기회를 제공하기 위해 최선을 다하고 있습니다.
News & Stories
삼성바이오에피스의 최신 소식과 이야기를 만나보세요.
NEWS
Feb 26, 2024
Feb 25, 2024
Feb 22, 2024
Feb 21, 2024
Feb 1, 2024
Today marks the 12th anniversary of Samsung Bioepis. We've been dedicated to #InnovatingAccess to #biosimilars since 2012. We are so proud of how far we’ve com...
Feb 28, 2024
Do any of these describe your eyesight: hazy, blurry, or cloudy? The Amsler grid test is a good method to check the state of your eyesight. Try the test below a...
Feb 27, 2024
On International Day of Women and Girls in Science, we remember the #women in #science who inspired today’s dreamers. Their achievements and courage have led to...
Feb 11, 2024
Inequity in cancer care prevents people from receiving crucial medical attention. Samsung Bioepis is committed to joining efforts to #CloseTheCareGap, ensuring ...
Feb 4, 2024
Every day, the lives of millions of people are affected by #RheumatoidArthritis. But there are ways to alleviate pain and control the chronic disease's progress...
Feb 2, 2024
Looking back to look forward. In a recent op-ed Pharmacy_Times, our VP Tom Newcomer reflects on what the past year has taught us about #biosimilar adoption in t...
LINKEDIN
Today we're celebrating our 12th anniversary. Since our beginnings, we've been committed to #InnovatingAccess to #biosimilars through our PassionforHealth. We a...
Hazy, blurry, and cloudy. Do any of these describe the current state of your eyesight? A good way to assess your vision is to try the Amsler grid test. Certain ...
#Women have continued to achieve tremendous feats in 해시태그#science to pave the way for the next generation. Thanks to their accomplishments and courage, various ...
Despite significant advancements in cancer care, inequity in this field prevents people from receiving crucial medical attention. Everyone should have equal acc...
#RheumatoidArthritis makes it harder for millions of people around the world to go about their daily activities and lives. However, there are ways to mitigate t...
More than a half year has passed since a slew of adalimumab biosimilars entered the US market. However, the stagnant rate of adalimumab biosimilar adoption in 2...
Join Us
삼성바이오에피스는 미래를 이끌어갈 인재를 기다리고 있습니다.
오늘 하루 그만보기 닫기
삼성바이오에피스 홈페이지에서 당사 소셜미디어 사이트로 이동하시겠습니까?